For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 16,022 | |||
| General and administrative | 12,252 | |||
| Total operating expenses | 28,274 | |||
| Loss from operations | -28,274 | |||
| Interest income | 1,411 | |||
| Total non-operating income | 1,411 | |||
| Net loss | -26,863 | |||
| Basic EPS | -0.25 | |||
| Diluted EPS | -0.25 | |||
| Basic Average Shares | 109,051,215 | |||
| Diluted Average Shares | 109,051,215 | |||
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)